Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.89
-7.21 (-10.29%)
Feb 25, 2026, 4:00 PM EST - Market closed
Cytokinetics Stock Forecast
Stock Price Forecast
The 17 analysts that cover Cytokinetics stock have a consensus rating of "Strong Buy" and an average price target of $86.12, which forecasts a 36.94% increase in the stock price over the next year. The lowest target is $41 and the highest is $136.
Price Target: $86.12 (+36.94%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 6 | 7 |
| Buy | 9 | 9 | 8 | 8 | 8 | 8 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 15 | 16 | 16 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $88 → $96 | Buy | Maintains | $88 → $96 | +52.65% | Feb 25, 2026 |
| Needham | Needham | Strong Buy Maintains $84 → $85 | Strong Buy | Maintains | $84 → $85 | +35.16% | Feb 25, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $95 → $101 | Buy | Maintains | $95 → $101 | +60.60% | Feb 20, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $84 → $92 | Strong Buy | Maintains | $84 → $92 | +46.29% | Feb 3, 2026 |
| Barclays | Barclays | Buy Initiates $87 | Buy | Initiates | $87 | +38.34% | Jan 28, 2026 |
Financial Forecast
Revenue This Year
121.08M
from 88.04M
Increased by 37.53%
Revenue Next Year
381.17M
from 121.08M
Increased by 214.81%
EPS This Year
-6.18
from -6.54
EPS Next Year
-4.48
from -6.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 243.1M | 505.6M | |||
| Avg | 121.1M | 381.2M | |||
| Low | 53.0M | 297.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 176.2% | 317.6% | |||
| Avg | 37.5% | 214.8% | |||
| Low | -39.8% | 145.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -4.85 | -1.17 | |||
| Avg | -6.18 | -4.48 | |||
| Low | -7.33 | -6.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.